Biological | Antiproliferative against Glioma Cells; Sensitizes Glioma Cells to TMZ |
Kogias, E.; Osterberg, N.; Baumer, B.; Psarras, N.; Koentges, C.; Papazoglou, A.; Saavedra, J. E.; Keefer, L. K.; Weyerbrock, A. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-p-activated nitric oxide donor PABA/NO in malignant gliomas. International Journal of Cancer 2012, 130 (5), 1184-1194.
|
Pubmed Abstract
|
Biological | Glutathionylation of Proteins |
Townsend, D. M.; Findlay, V. J.; Fazilev, F.; Ogle, M.; Fraser, J.; Saavedra, J. E.; Ji, X.; Keefer, L. K.; Tew, K. D. A glutathione S-transferase π-activated prodrug causes kinase activation concurrent with S-glutathionylation of proteins. Mol. Pharmacol. 2006, 69 (2), 501-508.
|
Pubmed Abstract
|
Biological | Mechanisms of Action |
Findlay, V. J.; Townsend, D. M.; Saavedra, J. E.; Buzard, G. S.; Citro, M. L.; Keefer, L. K.; Ji, X.; Tew, K. D. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Mol. Pharmacol. 2004, 65 (5), 1070-1079.
|
Pubmed Abstract
|
Chemical | Extended Release in Nanoparticles |
Kumar, V.; Hong, S. Y.; Maciag, A. E.; Saavedra J. E.; Adamson D. H.; Prud^homme R. K.; Keefer L. K.;Chakrapani H. Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO andDouble JS-K, through incorporation into PEG-protected nanoparticles. Mol. Pharmacol. 2010, 7 (1), 291-298.
|
Pubmed Abstract
|
Chemical | Structure Revision, Reactivity |
Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X.; Keefer L. K. PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J. Med. Chem. 2006, 49 (3), 1157-1164.
|
Pubmed Abstract
|
Patent | |
Saavedra J. E.; Keefer L. K.; Srinivasan, A.; Rice W. G.; Ji X.; Bogdan C. O2-arylated or O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and O2-substituted 1-[(2-carboxylato) pyrrolidin-1-yl] diazen-1-ium-1,2-diolate. U.S.Patent 6,610,660, August 2006.
|
|